Furthermore, as a downstream target of IGF-1, AKT expression increases in response to proteasome inhibitors in pre-clinical MM studies and bortezomib resistance could be overcome by AKT inhibition in an early phase clinical trials [80]. The gene discussed is IGF1; the disease is Miyoshi myopathy.